Until the mid 1950s, the anaesthetic agents in common use were sodium thiopentone (by then, used only for induction), the gases nitrous oxide and cyclopropane, and the volatile liquids ethyl chloride, diethyl ether and trichlorethylene.
In 1951, in response to encouragement from the British Medical Research Council to produce a nonflammable volatile anaesthetic agent, C. W. Suckling, 1 at Imperial Chemical Industries (lCI) in Cheshire, experimented with a number of halogenated ethanes. It was known that fluorine atoms added potency to a molecule, decreased the boiling-point, and increased molecular stability. A hydrogen atom was required for pharmacological activity, and other halogen atoms would modify potency. Only two of about one hundred new fluorine compounds reached clinical trial at that time-e.g. many halogenated aliphatics were rejected because they are gaseous at N.T.P. and are potential convulsants.
The most promising substance was halothane. Dr H. G. Epstein, the N.D.A. Physicist, on seeing the formula of halothane, remarked that it looked to be the type of compound that would not be stable over soda-lime. However, it was quickly confirmed that it was, in fact, stable over soda-lime, although an isomer of halothane which was another of the compounds developed at ICI was rejected for trial because it was unstable.
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Professor Macintosh commissioned Dr Roger Bryce-Smith (Professorial First Assistant) and myself (Nuffield Dominion Scholar) to conduct clinical trials using simple methods of administration, and to assess the safety, efficacy and potency of this new drug, which appeared to have the potential of being the first new agent of any consequence since the introduction of trichlorethylene in 1942. It is noteworthy that the breakdown of that drug over soda-lime was first reported by Dr Margaret McClelland, later to be a most distinguished Director of Anaesthetics at the Royal Children's Hospital in Melbourne.
There were no Ethics Committees in 1956 to consider such trials. We volunteered to conduct the initial administrations and trials on one another. Halothane in air was administered in varying concentrations until it had been determined how long it took for consciousness to be lost and subsequently regained at the various concentrations (tested by recall of auditory markers and reactions to painful stimuli), and also to measure respiratory depression, and changes in pulse rate, blood pressure, and ECG. We also tested higher concentrations to assess the potential to cause coughing, breathholding and laryngeal spasm.
After a few weeks we felt sufficiently confident with the drug to administer it to patients. We used halothane-air from the E.M.o. inhaler, and also by the open-drop method which was still widely in use with ether in the 1950s, especially in non-teaching hospitals.
The results of the clinical trial were published in the "British Medical Journal", 6 and shortly afterwards a meeting was held at the Royal Society of Medicine 7 at which further results were reported and a short film shown illustrating halothane administration.
Vigorous discussion followed the presentation and Dr Michael Johnstone spoke very favourably about his experience with halothane. Professor T. Cecil Gray from Liverpool was less enthusiastic about what he called "a smelly substance", and remarked-"I find it difficult to conceive that it will replace any of the agents at present at our disposa!: '7 Halothane gradually became available, but was very expensive-by a factor of about 15 in relation to trichlorethylene and ether and many hospitals were reluctant to buy it-as were the new vaporisers from which it would be administered safely. Some anaesthetists bought it themselves, placing a few millilitres in the vaporiser before induction.
Its bradycardic and hypotensive properties, its synergism with d-tubocurarine, and shivering during recovery were all noted from the beginning. 6 R. W. Virtue (personal communication) reported a case of "acute yellow atrophy" of the liver following a halothane anaesthetic in 1958, and hepatotoxic effects have been debated since then.
In 1966 the U.S. National Halothane Study 8 was published with a review 850,000 anaesthetics, of which 250,000 involved halothane. The incidence of liver failure varies with interpretation of the statistics, but Simpson et al 9 claim that only seven cases of massive hepatic necrosis could be possibly attributed to the anaesthetic, and that liver toxicity with halothane, if it existed at all, was extremely rare.
Blogg iO states that' 'halothane hepatitis is as rare as mortality related to anaesthesia itself", and notes that hepatotoxity after enflurane and isoflurane, although very rare, has been reported.
An editorial in the "Lancet", 11 also in 1986, stated that accurate figures for halothane-associated liver damage have been hard to obtain-estimates varying from 1 in 7000 to 1 in 30,000. This difficulty is not surprising in view of the lack of specific tests, and some undocumented reporting. While not questioning the occurrence of halothane-induced liver failure, the incidence could be less than alleged. In my own practice, three patients reported as having halothane hepatitis had anaesthetics not involving halothane, and I am aware of a fourth who had a spinal! The "Lancet" editorial notes the decline in halothane usage in the U.S. and U.K., and no doubt correctly attributes this to the advent of alternative volatile agents, and the perceived threat of litigation. It concludes that the use of halothane should not be abandoned because of the financial consequences, especially in less affluent countries and the low incidence of problems. Cut field 12 stated that while there is agreement that halothane can cause liver injury, it is very rare, and other life-threatening risks may occur with alternative drugs-e.g.immunosuppression, convulsions (propofol), respiratory depression (opioids), cardiovascular depression (local anaesthetics) and anaphylaxis-(most drugs, but in particular, muscle relaxants). The advent of desflurane and sevoflurane will further diminish the use of halothane. There are some departments in the U.S. where halothane cannot be used, except with the consent of the department head.
Oscar Wilde remarked that rumours reporting his death were greatly exaggerated, and likewise an obituary for halothane may be premature, but it does appear likely that halothane will disappear from clinical use before much longer, even though it is now the cheapest of the volatile agents and is still widely used, but ranks in popularity behind isoflurane and enflurane.
R. M. lones 13 states "it cannot be overemphasised how much an advance was the introduction of halothane. For the first time, the anaesthetist had an agent that was non-flammable, relatively non-toxic, and which allowed fairly rapid and clear-headed recovery".
Despite its drawbacks in its almost thirty-year history, halothane has greatly contributed to patient safety and comfort.
Vale!
